TREATMENT OF METABOLIC ALTERATIONS IN POLYCYSTIC OVARY SYNDROME

Authors

  • Ioana PAVALEANU University of Medicine and Pharmacy “Grigore T. Popa”-Iaşi
  • D. GAFITANU University of Medicine and Pharmacy “Grigore T. Popa”-Iaşi
  • Diana POPOVICI University of Medicine and Pharmacy “Grigore T. Popa”-Iaşi
  • Letitia Doina DUCEAC University “Apollonia”-Iaşi
  • Maricica PAVALEANU University “Apollonia”-Iaşi

Abstract

Polycystic ovary syndrome is a common endocrinopathy characterized by oligo ovulation or anovulation, signs of androgen excess and multiple small ovarian cysts. It includes various metabolic abnormalities: insulin resistance, hyperinsulinemia, impaired glucose tolerance, visceral obesity, inflammation and endothelial dysfunction, hypertension and dyslipidemia. All these metabolic abnormalities have long-term implications. Treatment should be individualized and must not address a single sign or symptom. Studies are still needed to determine the benefits and the associated risks of the medication now available to practitioners.

Author Biographies

  • Ioana PAVALEANU, University of Medicine and Pharmacy “Grigore T. Popa”-Iaşi

    Faculty of Medicine
    Department of Morpho-Functional Sciences

  • D. GAFITANU, University of Medicine and Pharmacy “Grigore T. Popa”-Iaşi

    Faculty of Medicine
    Department of Mother and Child Medicine

  • Diana POPOVICI, University of Medicine and Pharmacy “Grigore T. Popa”-Iaşi

    Faculty of Medicine
    Department of Mother and Child Medicine

  • Letitia Doina DUCEAC, University “Apollonia”-Iaşi

    Clinical Department

  • Maricica PAVALEANU, University “Apollonia”-Iaşi

    Clinical Department

References

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81: 19–25.
2. Ghemigian A, Vulpoi C, Păun D, Preda C. The etiopathogenetic hypotheses in polycystic ovary. Rev Med Chir Soc Med Nat 1997; 101(3-4):49-55.
3. Eleni Kandaraki, Charikleia Christakou, Evanthia Diamanti-KandarakiMetabolic syndrome and poly-cystic ovary syndrome... and vice versa. Arq Bras Endocrinol Metab. 2009; 53: 2.
4. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90(4): 1929-1935.
5. Vrbíková J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 2005; 11(3): 277–291.
6. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J. Clin. Endocrinol. Metab. 2008; 93(11): 4299–4306.
7. Ozdemir S, Görkemli H, Gezginç K, Ozdemir M, Kiyici A. Clinical and metabolic effects of medrox-yprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syn-drome. Int J Gynaecol Obstet 2008; 103(1): 44–49.
8. Vrbíková J, Stanická S, Dvoráková K, Hill M, Vondra K, Bendlová B, et al. Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjunction with peroral cyproterone acetate in women with polycystic ovary syndrome. Eur J Endocrinol 2004; 150(2): 215–223.
9. Costello MF, Shrestha B, Eden J, Johnson NP, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod 2007; 22(5): 1200–1209.
10. Nestler John E. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008; 358(1): 47–54.

Additional Files

Published

2016-06-30

Issue

Vol. 120 No. 2 (2016): The Medical-Surgical Journal

Section

INTERNAL MEDICINE - PEDIATRICS

License

COPYRIGHT 
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.

COPYRIGHT TRANSFER FORM FOR 

REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /

THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI

We, the undersigned authors of the manuscript entitled

_____________________________________________________________________________________

_____________________________________________________________________________________

warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.

  1. we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
  2. the manuscript does not break the intellectual property rights of any other person.
  3. we have read the submitted version of the manuscript and we are fully responsible for the content.

Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):

  1. ______________________________/_________________________
  2. ______________________________/_________________________
  3. ______________________________/_________________________

N.B.  All the authors must sign this form